The RAS family of proteins are one of the hottest targets in cancer research despite being one of the hardest for drug hunters to hit. Revolution Medicines has raised $238 million in an IPO to finance development of therapies that it says can drug these molecules in a novel way. On Wednesday evening, Revolution priced […]
Original Article: Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer